Amneal Pharmaceuticals Inc (FRA:2DT)
€ 7.7 0 (0%) Market Cap: 2.45 Bil Enterprise Value: 4.93 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 62/100

Amneal Pharmaceuticals Inc Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 Transcript

Aug 25, 2021 / 08:30PM GMT
Release Date Price: €4.7 (+4.91%)
Operator

Good afternoon, and thank you for joining us. We are here to share the positive results of the pivotal Phase III clinical trial of RISE-PD for IPX-203 for Parkinson's disease.

Today, we issued a press release announcing the top line findings. The press release and presentation are available on our website at amneal.com. We are conducting a live webcast of this call, a replay of which will also be available on our website after its conclusion.

Please note that certain statements made during the call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for future periods, are forward-looking statements. These statements are based solely on information that is now available to us. We encourage you to review the section entitled Cautionary Statements on Forward-Looking Statements in our press release and presentation, which applies to this call.

Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot